BACKGROUND: In patients with unresectable cholangiocarcinoma, photodynamic therapy (PDT) with porfimer sodium promotes biliary drainage and may improve survival and quality of life. AIM: To prospectively evaluate the safety and efficacy of PDT in patients with locally advanced biliary tract carcinoma. METHODS: Eligible patients had unresectable, histologically confirmed disease, a Karnofsky performance status of ≥30% and life expectancy >12 weeks. Patients received 2mg/kg i.v. of porfimer sodium, followed by endobiliary laser activation and stent replacement 48 h later. Patients were assessed clinically and radiologically before treatment and on day 28, and followed up thereafter at three-monthly intervals until death. RESULTS: 36 patients were entered over an 18 months period: 14 males, 22 females, with a median age of 65 (30-79)yr and performance status of 80 (50-100). PDT was technically successful in all cases and was generally well tolerated; there was no grade 4 toxicity and no treatment-associated mortality. The median survival was 12 (1-84) months. CONCLUSIONS: Porfimer sodium PDT can be delivered safely to patients with biliary tract cancer and is suitable for testing in phase III studies (UKCRN ID 1218).
BACKGROUND: In patients with unresectable cholangiocarcinoma, photodynamic therapy (PDT) with porfimer sodium promotes biliary drainage and may improve survival and quality of life. AIM: To prospectively evaluate the safety and efficacy of PDT in patients with locally advanced biliary tract carcinoma. METHODS: Eligible patients had unresectable, histologically confirmed disease, a Karnofsky performance status of ≥30% and life expectancy >12 weeks. Patients received 2mg/kg i.v. of porfimer sodium, followed by endobiliary laser activation and stent replacement 48 h later. Patients were assessed clinically and radiologically before treatment and on day 28, and followed up thereafter at three-monthly intervals until death. RESULTS: 36 patients were entered over an 18 months period: 14 males, 22 females, with a median age of 65 (30-79)yr and performance status of 80 (50-100). PDT was technically successful in all cases and was generally well tolerated; there was no grade 4 toxicity and no treatment-associated mortality. The median survival was 12 (1-84) months. CONCLUSIONS: Porfimer sodium PDT can be delivered safely to patients with biliary tract cancer and is suitable for testing in phase III studies (UKCRN ID 1218).
Authors: F Berr; M Wiedmann; A Tannapfel; U Halm; K R Kohlhaw; F Schmidt; C Wittekind; J Hauss; J Mössner Journal: Hepatology Date: 2000-02 Impact factor: 17.425
Authors: Franz Ludwig Dumoulin; Thomas Gerhardt; Sybille Fuchs; Christian Scheurlen; Michael Neubrand; Günter Layer; Tilman Sauerbruch Journal: Gastrointest Endosc Date: 2003-06 Impact factor: 9.427
Authors: C S Shim; Y K Cheon; S W Cha; S Bhandari; J H Moon; Y D Cho; Y S Kim; L S Lee; M S Lee; B S Kim Journal: Endoscopy Date: 2005-05 Impact factor: 10.093
Authors: Helmut Witzigmann; Frieder Berr; Ulrike Ringel; Karel Caca; Dirk Uhlmann; Konrad Schoppmeyer; Andrea Tannapfel; Christian Wittekind; Joachim Mossner; Johann Hauss; Marcus Wiedmann Journal: Ann Surg Date: 2006-08 Impact factor: 12.969
Authors: M A Ortner; J Liebetruth; S Schreiber; M Hanft; U Wruck; V Fusco; J M Müller; H Hörtnagl; H Lochs Journal: Gastroenterology Date: 1998-03 Impact factor: 22.682
Authors: Werner Dolak; Hubert Schwaighofer; Brigitte Hellmich; Bernhard Stadler; Georg Spaun; Wolfgang Plieschnegger; Arnold Hebenstreit; Jutta Weber-Eibel; Franz Siebert; Klaus Emmanuel; Peter Knoflach; Michael Gschwantler; Wolfgang Vogel; Michael Trauner; Andreas Püspök Journal: United European Gastroenterol J Date: 2016-07-07 Impact factor: 4.623
Authors: Stephen P Pereira; Mark Jitlal; Marian Duggan; Emma Lawrie; Sandy Beare; Pam O'Donoghue; Harpreet S Wasan; Juan W Valle; John Bridgewater; John Ramage; Robert Przemioslo; Richard Hammonds; Guru Aithal; Frank Murphy; Graham Foster; Richard Sturgess Journal: ESMO Open Date: 2018-07-23